83 Result(s)

Article

Impact of cytogenetic classification on outcomes following early high-dose therapy in multiple myeloma

Early high-dose therapy (HDT), consisting of high-dose melphalan and autologous stem cell transplantation following doublet or triplet novel agent induction, is a preferred management strategy for transplant-e...

G P Kaufman, M A Gertz, A Dispenzieri, M Q Lacy, F K Buadi, D Dingli… in Leukemia (2016)

Article

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation

In patients with multiple myeloma (MM) undergoing autologous hematopoietic cell transplantation (auto-HCT), peripheral blood progenitor cells may be collected following mobilization with growth factor alone (G...

G L Uy, L J Costa, P N Hari, M-J Zhang, J-X Huang… in Bone Marrow Transplantation (2015)

Article

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy

Normalization of the serum-free light-chain ratio (FLCr) with the absence of bone marrow monoclonal plasma cells following achievement of a complete response (CR) to therapy denotes a stringent CR in multiple ...

M Alhaj Moustafa, S V Rajkumar, A Dispenzieri, M A Gertz, M Q Lacy, F K Buadi… in Leukemia (2015)

Article

Racial disparities in the prevalence of monoclonal gammopathies: a population-based study of 12 482 persons from the National Health and Nutritional Examination Survey

Multiple myeloma (MM) incidence is markedly higher in blacks compared with whites, which may be related to a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS). Our objective was to...

O Landgren, B I Graubard, J A Katzmann, R A Kyle, I Ahmadizadeh, R Clark… in Leukemia (2014)

Article

Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients

Therapy for multiple myeloma (MM) has markedly changed in the past decade with the introduction of new drugs, but it is not clear whether the improvements have been sustained. We studied 1038 patients diagnose...

S K Kumar, A Dispenzieri, M Q Lacy, M A Gertz, F K Buadi, S Pandey, P Kapoor… in Leukemia (2014)

Article

Second transplants for multiple myeloma relapsing after a previous autotransplant—reduced-intensity allogeneic vs autologous transplantation

There is no standard therapy for multiple myeloma relapsing after an autotransplant. We compared the outcomes of a second autotransplant (N=137) with those of an allotransplant (N=152) after non-myeloablative or ...

C O Freytes, D H Vesole, J LeRademacher, X Zhong, R P Gale… in Bone Marrow Transplantation (2014)

Article

Long-term response to lenalidomide in patients with newly diagnosed multiple myeloma

T V Kourelis, S K Kumar, G Srivastava, M A Gertz, M Q Lacy, F K Buadi, R A Kyle… in Leukemia (2014)

Article

Impact of primary molecular cytogenetic abnormalities and risk of progression in smoldering multiple myeloma

We studied 351 patients with smoldering multiple myeloma (SMM) in whom the underlying primary molecular cytogenetic subtype could be determined based on cytoplasmic immunoglobulin fluorescent in situ hybridizatio...

S V Rajkumar, V Gupta, R Fonseca, A Dispenzieri, W I Gonsalves, D Larson… in Leukemia (2013)

Article

Risk of acute leukemia and myelodysplastic syndromes in patients with monoclonal gammopathy of undetermined significance (MGUS): a population-based study of 17 315 patients

The purpose of this study was to determine if there is an increased risk of acute leukemia and myelodysplastic syndromes (MDS) in persons with monoclonal gammopathy of undetermined significance (MGUS). We used...

L E Roeker, D R Larson, R A Kyle, S Kumar, A Dispenzieri, S V Rajkumar in Leukemia (2013)

Article

Serum free light chain ratio as a biomarker for high-risk smoldering multiple myeloma

A markedly elevated serum free light chain (FLC) ratio may serve as a biomarker for malignant transformation in high-risk smoldering multiple myeloma (SMM) and identify patients who are at imminent risk of pro...

J T Larsen, S K Kumar, A Dispenzieri, R A Kyle, J A Katzmann, S V Rajkumar in Leukemia (2013)

Article

Treatment patterns and outcomes in elderly patients with multiple myeloma

S-M Bang, R A Kyle, S V Rajkumar, S Kumar in Leukemia (2013)

Article

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

Plasma cell leukemia (PCL) is a rare and aggressive variant of myeloma characterized by the presence of circulating plasma cells. It is classified as either primary PCL occurring at diagnosis or as secondary P...

C Fernández de Larrea, R A Kyle, B G M Durie, H Ludwig, S Usmani, D H Vesole… in Leukemia (2013)

Article

High levels of peripheral blood circulating plasma cells as a specific risk factor for progression of smoldering multiple myeloma

Smoldering multiple myeloma (SMM) carries a 50% risk of progression to multiple myeloma (MM) or related malignancy within the first 5 years following diagnosis. The goal of this study was to determine if high ...

G Bianchi, R A Kyle, D R Larson, T E Witzig, S Kumar, A Dispenzieri, W G Morice… in Leukemia (2013)

Article

Single-nucleotide polymorphism rs1052501 associated with monoclonal gammopathy of undetermined significance and multiple myeloma

A J Greenberg, A M Lee, D J Serie, S K McDonnell, J R Cerhan, M Liebow… in Leukemia (2013)